LFRET, a novel rapid assay for anti-tissue transglutaminase antibody detection.
The diagnosis of celiac disease (CD) is currently based on serology and intestinal biopsy, with detection of anti-tissue transglutaminase (tTG) IgA antibodies recommended as the first-line test. Emphasizing the increasing importance of serological testing, new guidelines and evidence suggest basing...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0225851 |
id |
doaj-75a33ef95d1c4b5bbf4e20ad332950fc |
---|---|
record_format |
Article |
spelling |
doaj-75a33ef95d1c4b5bbf4e20ad332950fc2021-03-03T21:16:37ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-011411e022585110.1371/journal.pone.0225851LFRET, a novel rapid assay for anti-tissue transglutaminase antibody detection.Juuso RusanenAnne ToivonenJussi HepojokiSatu HepojokiPekka ArikoskiMarkku HeikkinenOuti VaaralaJorma IlonenKlaus HedmanThe diagnosis of celiac disease (CD) is currently based on serology and intestinal biopsy, with detection of anti-tissue transglutaminase (tTG) IgA antibodies recommended as the first-line test. Emphasizing the increasing importance of serological testing, new guidelines and evidence suggest basing the diagnosis solely on serology without confirmatory biopsy. Enzyme immunoassays (EIAs) are the established approach for anti-tTG antibody detection, with the existing point-of-care (POC) tests lacking sensitivity and/or specificity. Improved POC methods could help reduce the underdiagnosis and diagnostic delay of CD. We have previously developed rapid homogenous immunoassays based on time-resolved Förster resonance energy transfer (TR-FRET), and demonstrated their suitability in serodiagnostics with hanta- and Zika virus infections as models. In this study, we set out to establish a protein L -based TR-FRET assay (LFRET) for the detection of anti-tTG antibodies. We studied 74 patients with biopsy-confirmed CD and 70 healthy controls, with 1) the new tTG-LFRET assay, and for reference 2) a well-established EIA and 3) an existing commercial POC test. IgG depletion was employed to differentiate between anti-tTG IgA and IgG positivity. The sensitivity and specificity of the first-generation tTG-LFRET POC assay in detection of CD were 87.8% and 94.3%, respectively, in line with those of the reference POC test. The sensitivity and specificity of EIA were 95.9% and 91.9%, respectively. This study demonstrates the applicability of LFRET to serological diagnosis of autoimmune diseases in general and of CD in particular.https://doi.org/10.1371/journal.pone.0225851 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Juuso Rusanen Anne Toivonen Jussi Hepojoki Satu Hepojoki Pekka Arikoski Markku Heikkinen Outi Vaarala Jorma Ilonen Klaus Hedman |
spellingShingle |
Juuso Rusanen Anne Toivonen Jussi Hepojoki Satu Hepojoki Pekka Arikoski Markku Heikkinen Outi Vaarala Jorma Ilonen Klaus Hedman LFRET, a novel rapid assay for anti-tissue transglutaminase antibody detection. PLoS ONE |
author_facet |
Juuso Rusanen Anne Toivonen Jussi Hepojoki Satu Hepojoki Pekka Arikoski Markku Heikkinen Outi Vaarala Jorma Ilonen Klaus Hedman |
author_sort |
Juuso Rusanen |
title |
LFRET, a novel rapid assay for anti-tissue transglutaminase antibody detection. |
title_short |
LFRET, a novel rapid assay for anti-tissue transglutaminase antibody detection. |
title_full |
LFRET, a novel rapid assay for anti-tissue transglutaminase antibody detection. |
title_fullStr |
LFRET, a novel rapid assay for anti-tissue transglutaminase antibody detection. |
title_full_unstemmed |
LFRET, a novel rapid assay for anti-tissue transglutaminase antibody detection. |
title_sort |
lfret, a novel rapid assay for anti-tissue transglutaminase antibody detection. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2019-01-01 |
description |
The diagnosis of celiac disease (CD) is currently based on serology and intestinal biopsy, with detection of anti-tissue transglutaminase (tTG) IgA antibodies recommended as the first-line test. Emphasizing the increasing importance of serological testing, new guidelines and evidence suggest basing the diagnosis solely on serology without confirmatory biopsy. Enzyme immunoassays (EIAs) are the established approach for anti-tTG antibody detection, with the existing point-of-care (POC) tests lacking sensitivity and/or specificity. Improved POC methods could help reduce the underdiagnosis and diagnostic delay of CD. We have previously developed rapid homogenous immunoassays based on time-resolved Förster resonance energy transfer (TR-FRET), and demonstrated their suitability in serodiagnostics with hanta- and Zika virus infections as models. In this study, we set out to establish a protein L -based TR-FRET assay (LFRET) for the detection of anti-tTG antibodies. We studied 74 patients with biopsy-confirmed CD and 70 healthy controls, with 1) the new tTG-LFRET assay, and for reference 2) a well-established EIA and 3) an existing commercial POC test. IgG depletion was employed to differentiate between anti-tTG IgA and IgG positivity. The sensitivity and specificity of the first-generation tTG-LFRET POC assay in detection of CD were 87.8% and 94.3%, respectively, in line with those of the reference POC test. The sensitivity and specificity of EIA were 95.9% and 91.9%, respectively. This study demonstrates the applicability of LFRET to serological diagnosis of autoimmune diseases in general and of CD in particular. |
url |
https://doi.org/10.1371/journal.pone.0225851 |
work_keys_str_mv |
AT juusorusanen lfretanovelrapidassayforantitissuetransglutaminaseantibodydetection AT annetoivonen lfretanovelrapidassayforantitissuetransglutaminaseantibodydetection AT jussihepojoki lfretanovelrapidassayforantitissuetransglutaminaseantibodydetection AT satuhepojoki lfretanovelrapidassayforantitissuetransglutaminaseantibodydetection AT pekkaarikoski lfretanovelrapidassayforantitissuetransglutaminaseantibodydetection AT markkuheikkinen lfretanovelrapidassayforantitissuetransglutaminaseantibodydetection AT outivaarala lfretanovelrapidassayforantitissuetransglutaminaseantibodydetection AT jormailonen lfretanovelrapidassayforantitissuetransglutaminaseantibodydetection AT klaushedman lfretanovelrapidassayforantitissuetransglutaminaseantibodydetection |
_version_ |
1714817827828924416 |